

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au*For Immediate Release*

Melbourne, Australia — 31 January 2012

Inavir[®] Q2 royalties

Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo Co., Ltd. have provided written confirmation that Inavir[®] gross sales were JPY1.7bn and indicative royalties were \$687,000 in the 3 months to 31 December 2011.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo Co., Ltd. co-own a range of second generation influenza antivirals, of which the lead product Inavir[®], is approved for marketing in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.

Inavir[®] is registered to Daiichi Sankyo.

Investor / Analyst Enquiries**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Media Enquiries

Tim Duncan, Hinton & Associates

T: +61 3 9600 1979 / M: +61 408 441 122

US Enquiries

Hershel Berry, Blueprint Life Science Group

M: +1 415 505 3749